Oceania · Regional markets · Stockhead

Orthocell partner receives US FDA clearance for marine-derived bone graft

Published by Stockhead · Australia 1 h ago

Perth-based Orthocell has finalised a strategic investment in Marine Biomedical in January 2026, increasing its equity interest to 12% for ... Read More The post Orthocell partner…

Read the full article on Stockhead Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stockhead.com.au)

Also worth reading

The Motley Fool Australia

Uranium price tipped to rise 38%. Here's why and the ASX shares brokers rate a buy

Business News (WA)

Orthocell partner receives US FDA clearance for marine-derived bone graft

Share

Also worth reading

Uranium price tipped to rise 38%. Here's why and the ASX shares brokers rate a buy

Westbridge buys $43m QLD medical asset

You don't need to miss a payment to get help

North Korea denies role in Binance heist as customers withdraw billions

Carry It Like Makybe

IFM Investors appoints global product strategy head